News | January 31, 2022
Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Biocon has reported consolidated financial results for the period ended December 31, 2021
The stability is led by healthy demand in the domestic and emerging markets
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Subscribe To Our Newsletter & Stay Updated
